DiaMedica to expand into neurological disorders through acquisition of Sanomune

Biopharmaceutical company DiaMedica announced its intention to acquire all of the issued and outstanding shares of Sanomune Inc., a privately held biopharmaceutical company developing treatments for neurological and autoimmune diseases. Named a Top 10 Canadian Life Sciences Company for 2008/2009, Sanomune’s current pipeline includes a promising neuroprotective protein that also triggers neural stem cell proliferation.

Click here to read more.

Share this: